Business
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with elevated CVD risk; readout of expanded GFORCE-1 trial in subjects with elevated CVD risk anticipated in H2 2026 Company expects to initiate multiple MRT-8102 Phase 2 studies, including in patients with elevated atherosclerotic risk in H2 2026, in patients with gout flares in Q4 2026/Q1 2027, and in patients with moderate to severe hidradenitis suppurativa in H1 2027 Prese
About this update from Monte Rosa Therapeutics, Inc.
[{"type":"image","alt":"Monte Rosa Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Monte Rosa Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":82,"url":"https://media.zenfs.com/en/globenewswire.com/c99f028be58427489eba79299e175651"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fIhey1p_FM7t0hRxxCU_wA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNQ--/https://media.zenfs.com/en/globenewswire.com/c99f028be58427489eba79299e175651","width":300,"height":82},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/fIhey1p_FM7t0hRxxCU_wA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNQ--/https://media.zenfs.com/en/globenewswire.com/c99f028be58427489eba79299e175651","width":300,"height":82}},"lazy":false},{"type":"text","content":"Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with elevated CVD risk; readout of expanded GFORCE-1 trial in subjects with elevated CVD risk anticipated in H2 2026","length":237,"tagName":"p"},{"type":"text","content":"Company expects to initiate multiple MRT-8102 Phase 2 studies, including in patients with elevated atherosclerotic risk in H2 2026, in patients with gout flares in Q4 2026/Q1 2027, and in patients with moderate to severe hidradenitis suppurativa in H1 2027 ","length":256,"tagName":"p"},{"type":"text","content":"Presented positive interim Phase 1/2 clinical data of GSPT1-directed MGD MRT-2359 in combination with an AR inhibitor in mCRPC patients with AR mutations; initiation of Phase 2 study evaluating MRT-2359 in combination with apalutamide in mCRPC patients with AR mutations planned for Q3 2026 ","length":290,"tagName":"p"},{"type":"text","content":"VAV1-directed MGD MRT-6160 advancing toward anticipated initiation by Novartis of multiple Phase 2 studies in immune-mediated diseases","length":139,"tagName":"p"},{"type":"text","content":"Preclinical data presented at AACR highlight a novel cyclin E1-directed MGD with superior selectivity and reduced off-target activity compared to CDK2 inhibitors; IND submission anticipated in H2 2026","length":200,"tagName":"p"},{"type":"text","content":"Strong balance sheet with cash, cash equivalents, restricted cash, and marketable securities of $671 million, expected to support operations into 2029","length":151,"tagName":"p"},{"type":"text","conten...